51 results about "Serum lipid levels" patented technology

This invention provides a *Lactobacillus plantarum* LN-Lp1 strain, its applications, products, and methods, belonging to the field of probiotic technology. The *Lactobacillus plantarum* LN-Lp1 strain has the accession number CGMCC 33158. This LN-Lp1 strain was deposited on December 23, 2024, at the China General Microbiological Culture Collection Center, located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing. Based on this strain, this invention also provides its uses and related products. This LN-Lp1 strain exhibits strong resistance to simulated gastric-intestinal stress and good intestinal adhesion and colonization potential. The *Lactobacillus plantarum* LN-Lp1 of this invention has excellent weight-loss effects, improving lipid metabolism and lowering blood lipid levels.

The present application relates to a kind of pharmaceutical composition for treating type 2 diabetes and its application.The pharmaceutical composition includes icariin, hydroxymethyl coumarin and cinnamaldehyde, by three-component synergistic effect, simultaneously act on insulin resistance, pancreatic beta cell apoptosis and systemic metabolic inflammation three type 2 diabetes core pathological links, auxiliary reduce serum lipid level, and reduce drug-related liver injury risk, good safety.Animal experiment results show that three-drug combination group can effectively reduce blood sugar (decrease about 50%), significantly improve islet structure atrophy, restore hepatocyte index arrangement, reduce glomerular hypertrophy, significantly reduce serum TG and CHOL level (P<0.05) and inflammatory factor IL-6 and TNF-alpha level (P<0.05), and avoid the hepatotoxicity risk (ALT / AST restores to close to normal level) of hydroxymethyl coumarin.The present application is composed of three kinds of natural monomers with clear structure, and has clear components and controllable quality, which provides a more optimal comprehensive treatment strategy for the treatment of type 2 diabetes and its complications.

The application relates to the technical field of microbial fermentation, and discloses a lily fermentation product for improving blood lipid, a preparation method and application thereof. Lily raw materials are taken as fermentation objects, and suitable lactobacillus plantarum fermentation strains are selected to ferment the lily raw materials to obtain a lily fermentation product. Compared with other fermentation products of lactobacillus plantarum, the lily fermentation product of the lactobacillus plantarum of CICC 25125 has more excellent pancreatic lipase inhibition capacity and has the effect of promoting and improving blood lipid levels, thereby providing a better basis for the application of the lily fermentation product in the food field.

The application discloses medical use of gelated cells loaded with sulfonated chitosan in treatment of atherosclerosis, and belongs to the technical field of biological medicine. The gelated cells loaded with sulfonated chitosan take macrophages as host cells, and intracellular cross-linking forms a photocrosslinking hydrogel network composed of methacrylated hyaluronic acid and sulfonated chitosan. The gelated cells completely retain cell membrane structure and membrane surface protein expression, lose the proliferation ability, and have excellent blood lipid selective adsorption capacity and foam cell lipid metabolism regulation capacity. In-vivo and in-vitro experiments prove that the gelated cells can significantly reduce blood lipid levels of atherosclerosis model animals, reduce aortic plaque area, and have good biological safety, thereby providing a new strategy and candidate drug for prevention and treatment of atherosclerosis, and having a good clinical application prospect.

The application discloses a norchizhiol triterpenoid compound, a preparation method and application thereof. The norchizhiol triterpenoid compound norchizhiol A can be quickly prepared from Ganoderma lucidum. The test proves that the norchizhiol A can inhibit the accumulation of triglyceride in the differentiation process of 3T3L1 preadipocytes. The norchizhiol A can also effectively reduce the weight increase and liver coefficient of high-fat-diet-induced obese mice, regulate the blood lipid level of the obese mice, and significantly intervene and improve the lipoprotein distribution of the body. The compound can be used for preparing anti-obesity and lipid-lowering medicines.

The present disclosure relates to a use of Lacticaseibacillus rhamnosus FMBL L23004 CNN in the preparation of a medicament for preventing or treating diabetes mellitus. The Lacticaseibacillus rhamnosus FMBL L23004 CNN was deposited with the China Center for Type Culture Collection (CCTCC) on 26 Jun. 2023 under the accession number CCTCC NO: M 20231099. The Lacticaseibacillus rhamnosus FMBL L23004 CNN strain has the effect of inhibiting the activity of α-glucosidase, α-amylase, and dipeptidyl peptidase IV. Administration of the strain can significantly lower oral glucose tolerance and insulin tolerance in Type 2 Diabetes Mellitus (T2DM) mice, reduce abnormal postprandial blood glucose fluctuations, decrease fasting blood glucose levels, lower fasting insulin levels, reduce blood lipid levels, and alleviate insulin resistance. The strain significantly improves the composition of the gut microbiome, increases the abundance and diversity of beneficial gut bacteria, and reduces the relative abundance of pathogenic bacteria.

The invention belongs to the technical field of biological medicine, and particularly relates to application of LRRFIP1 serving as a bilberry extract to improvement of a target spot of insulin resistance of gestational diabetes mellitus. The insulin resistance of gestational diabetes mellitus is improved by specifically regulating and controlling a PI3K-AKT signal channel and a GLUT4 glucose transporter function in skeletal muscle based on the bilberry extract. The bilberry extract used in the invention is a natural plant source, is high in safety, and is suitable for pregnancy. PI3K-AKT signal channels can be activated at the same time, and insulin resistance and lipid metabolism disorder can be synergistically improved. The action mechanism is systematically illuminated through technical means such as proteomics, network pharmacology, molecular docking and the like. Glucose tolerance, insulin sensitivity and blood fat level of GDM rats can be remarkably improved, and no remarkable side effect exists.

This invention belongs to the technical field of natural product active ingredients, specifically relating to a glycopeptide LBGP-I-b derived from wolfberry and its uses. The glycopeptide LBGP-I-b has an average molecular weight of 700–1000 Da, a polypeptide content of 70%–80%, and a polysaccharide content of 10%–20%. The sugar chains are composed of glucose residues, and the sugar chains are linked to the peptide chains via O-glycopeptide bonds. The glycopeptide has functions such as regulating lipid metabolism, lowering blood lipid levels, and improving liver function. The glycopeptide of this invention has a clear source and stable properties, and has good application prospects in the prevention and treatment of metabolic diseases such as metabolic-related fatty liver disease.

The present invention relates to an immunogenic compound comprising an ApoB100 epitope, an immunogenic composition comprising the same, and uses thereof. The immunogenic compound can be used to prevent or treat diseases caused by increased ApoB100 levels or increased lipid levels by inducing an immune response to the ApoB100 epitope. The immunogenic compound has a complementary mechanism to GIP-1R agonist obesity treatments, so their combined or concurrent administration can enhance weight loss and improve side effects associated with long-term administration of GIP-1R agonist obesity treatments by improving weight loss plateaus, delaying the yo-yo effect, and improving lean body mass reduction.

The invention provides application of nitraria tangutorum bobr extract in preparation of products for regulating glycolipid metabolism disorder, and relates to the technical field of plant extract application. The nitraria macrocarpa extract is a composition rich in alkaloid and flavonoid compounds, wherein the sum of the content of total alkaloid and the content of total flavonoids is not lower than 85% of the total weight of the extract. The extract is prepared through the processes of fresh fruit juicing, alcohol precipitation impurity removal and AB-8 macroporous resin gradient elution. Experiments show that the extract can significantly reduce fasting blood glucose of type 2 diabetes mice induced by high-fat and high-sugar diet combined with STZ, improve sugar tolerance and insulin resistance, and synchronously regulate the blood fat level, and shows an excellent glucose and lipid metabolism synergistic improvement effect. The extract disclosed by the invention provides a choice for developing a safe and effective glycolipid metabolism regulator.

The invention relates to an application of oligosporine in preparation of a weight-reducing medicine. The invention finds that the oligosporine B can reduce the weight of mammals. Moreover, the further research finds that the weight loss of mammals can be realized due to the fact that triglyceride in fat cells is hydrolyzed into free fatty acid and glycerol by mainly enhancing the activity of a key rate-limiting enzyme responsible for lipid metabolism in the fat cells so as to reduce the blood fat level and lipid accumulation in the fat cells, so that the weight loss of the mammals can be realized. Therefore, the weight loss is realized by reducing the adipose tissue mass.

The application discloses a traditional Chinese medicine composition for treating atherosclerosis combined with hyperhomocysteinemia. The traditional Chinese medicine composition is prepared from the following raw medicinal materials: Radix Rehmanniae Preparata 12-15 parts, Cistanche 9-12 parts, Radix Astragali 12-15 parts, Cyperus rotundus 6-9 parts, Salvia miltiorrhiza 15-30 parts and safflower 6-9 parts. In addition, the application also relates to a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition has obvious effects of treating atherosclerosis, reducing homocysteine and blood lipid levels, improving patient symptoms and reducing atherosclerosis-related complications.

The present application mainly relates to a kind of composition for reducing fat and losing weight and its preparation method and application, belong to the field of biotechnology.The composition of the present application includes Cordyceps flower fruit body granules 30-60 parts, Morel fruit body granules 5-20 parts, bitter buckwheat flour 10-25 parts, mulberry leaf water extract 10-25 parts, Huangjing water extract 5-21 parts and Cassia seed water extract 1-6 parts.The above raw materials are mixed to obtain the composition of the present application.The composition of the present application can improve the blood lipid level of hyperlipidemia, inhibit the increase of body weight, reduce the volume of white adipose cells, inhibit the deposition of liver lipid, reverse the damage of liver tissue and liver function, effectively reduce fat and lose weight, and play a role in treating hyperlipidemia, obesity and fatty liver.

The invention belongs to the technical field of pharmaceutical preparations, and provides a probucol sustained-release capsule for reducing the blood fat level and a preparation method thereof, and the probucol sustained-release capsule is prepared by filling a capsule shell with sustained-release pellets, the sustained-release pellet comprises a blank pellet core, a medicine carrying layer, an isolating layer and a sustained-release layer from inside to outside, wherein the medicine carrying layer comprises probucol and an adhesive in a mass ratio of (200-250): (8-12); the slow-release layer is prepared from eudragit RL PO, a plasticizer, a pore-foaming agent and an anti-sticking agent according to the mass ratio of (250 to 300) to (20 to 25) to (20 to 22) to (10 to 18); the pore-foaming agent is prepared from polyethylene glycol 400 and PVP K25 in a mass ratio of (8-12): (3-5). The probucol sustained-release capsule provided by the invention not only has an excellent sustained-release effect, but also enables drug absorption to be less affected by gastric emptying, reduces stimulation to gastrointestinal tracts, and can improve patient compliance.

The invention discloses an application of an REV-ERB alpha agonist SR9009 in preparation of a medicine for preventing and treating thoracic aortic aneurysm and dissection. The invention provides an application of an REV-ERB alpha agonist SR9009 in preparation of a medicine for preventing and / or treating thoracic aortic aneurysm and dissection. The step of preventing and treating the TAAD comprises the substeps of reducing the incidence rate of the TAAD and relieving cavities and / or fractures of the middle-layer structure of the thoracic aorta. Through intraperitoneal injection of the SR9009 in a TAAD mouse model, the result shows that the SR9009 can significantly reduce BAPN-induced mouse thoracic aorta VSMC apoptosis and elastic fiber degradation, and improve the histopathologic change of TAAD; the blood pressure, the body weight and the blood fat level of the mouse are not obviously influenced by the administration of the SR9009, and the SR9009 has good safety, so that the SR9009 provided by the invention has a good clinical application prospect.

The invention discloses an application of a BMAL1 activator ISX-9 in preparation of a medicine for preventing and treating thoracic aortic aneurysm and dissection. The invention provides an application of a BMAL1 activator ISX-9 in preparation of a medicine for preventing and / or treating thoracic aortic aneurysm and dissection. The step of preventing and treating the TAAD comprises the substeps of reducing the incidence rate of the TAAD and relieving cavities and / or fractures of the middle-layer structure of the thoracic aorta. According to the application disclosed by the invention, ISX-9 is subjected to intraperitoneal injection in a TAAD mouse model, and a result shows that the ISX-9 can be used for remarkably reducing BAPN-induced mouse thoracic aorta VSMC apoptosis and elastic fiber degradation and improving the histopathologic change of TAAD; the blood pressure, the body weight and the blood fat level of the mouse are not obviously influenced by the administration of the ISX-9, and the ISX-9 has good safety, so that the ISX-9 provided by the invention has a good clinical application prospect.

The invention provides a traditional Chinese medicine composition and application thereof in preparation of a medicine for treating atherosclerosis, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition comprises the following raw material components in parts by mass: 8-10 parts of Guangxi curcuma zedoary, 8-12 parts of peach kernels, 8-12 parts of cassia twigs, 8-12 parts of poria cocos, 25-35 parts of raw astragalus membranaceus, 8-12 parts of moutan bark, 8-12 parts of red peony roots, 10-20 parts of fructus mali, 10-15 parts of herba lycopi and 25-35 parts of oysters. The traditional Chinese medicine composition can improve the lesion degree of atherosclerosis, reduce the blood fat level and reduce the generation of atheromatous plaques, thereby improving the atherosclerosis; meanwhile, the traditional Chinese medicine composition has an anti-AS effect in the aspects of stabilizing vulnerable plaques, promoting reverse transport of cholesterol, adjusting energy metabolism and water metabolism of mitochondria, resisting inflammation and resisting oxidative stress.

The invention provides gynura divaricata polysaccharide as well as a preparation method and application thereof, and belongs to the field of polysaccharide preparation. The homogeneous component GDP1 of the gynura divaricata polysaccharide is mainly prepared from fructose, glucose, arabinose and galactose according to the molar ratio of 58.4: 39.08: 0.75: 0.78; the molecular weight Mw is 6684Da, and the purity is 99.04%; t2DM mouse in-vivo hypoglycemic activity research is carried out, and the prepared gynura divaricata polysaccharide can relieve the symptom of weight loss of mice, relieve the hyperglycemia and insulin resistance level of the mice and regulate the abnormal conditions of the blood fat level, the oxidative stress level and the inflammation level of the mice. The PI3K / Akt / GLUT-4 signal channel is activated to increase the glucose uptake of the T2DM mouse and reduce the insulin resistance of the T2DM mouse, so that the blood glucose metabolism of the T2DM mouse is improved. The gynura divaricata polysaccharide can be used for preparing medicines for treating type 2 diabetes mellitus.

The application provides a lactobacillus sakei LN-Ls1 with weight loss and lipid-lowering effects and an application thereof, and belongs to the technical field of microorganisms. The lactobacillus sakei LN-Ls1 has a preservation number of CGMCC 30611. The LN-Ls1 strain is preserved in the China General Microbiological Culture Collection Center on May 13, 2024, and the address is No. 1, Beichen West Road, Chaoyang District, Beijing. Based on the strain, the application also provides the use and related products thereof. The lactobacillus sakei LN-Ls1 can significantly reduce body weight, improve blood lipid level and lipid metabolism without affecting food intake, has a remarkable weight loss and lipid-lowering effect, and has a better technical effect compared with existing products, and has good safety and application prospect.

The invention discloses an application of jujuboside A in preparation of an anti-atherosclerosis drug, which can significantly inhibit formation of atherosclerotic plaques, improve vascular functions and reduce blood fat level, has obvious effects, and is safe and reliable.

The present application relates to a sustained-release pharmaceutical composition of GLP-1 receptor agonist and a preparation method thereof. The composition comprises 0.05-0.5 wt% active ingredient, 45-85 wt% sustained-release agent, and 15-55 wt% viscosity reducer, or comprises 0.05-0.5 wt% active ingredient and 45-99.95 wt% thermal sensitive sustained-release agent. The active ingredient is GLP-1 receptor agonist, the sustained-release agent is polyorthoester, and the viscosity reducer is preferably glycerate compound. The present application also provides a pharmaceutical combination product comprising the sustained-release pharmaceutical composition, and application of the composition in treating metabolic related diseases. The sustained-release pharmaceutical composition has significantly improved pharmacokinetic characteristics, can realize long-acting administration, improve patient compliance, and shows excellent effects in improving blood glucose control, promoting weight loss, and improving blood lipid level.

Provided are a sustained-release pharmaceutical composition of a GLP-1 receptor agonist and a preparation method therefor. The composition contains 0.05 wt% to 0.5 wt% of an active ingredient, 45 wt% to 85 wt% of a sustained-release agent, and 15 wt% to 55 wt% of a viscosity-reducing agent, or contains 0.05 wt% to 0.5 wt% of an active ingredient, and 45 wt% to 99.95 wt% of a thermal sensitive sustained-release agent, wherein the active ingredient is a GLP-1 receptor agonist, the sustained-release agent is a polyorthoester, and the viscosity-reducing agent is preferably a glyceryl ester compound. Further provided are a drug-medical device combination product containing the sustained-release pharmaceutical composition, wherein the drug is the above-described sustained-release drug, and the medical device is a jet microneedle capable of injecting high-viscosity substances, and the use of the composition in the treatment of metabolism-related diseases. The sustained-release pharmaceutical composition has significantly improved pharmacokinetic characteristics, can realize long-acting administration, improves patient compliance, and exhibits good effects in improving blood glucose control, promoting weight loss, improving blood lipid levels, etc.

The application discloses application of a water-soluble tomato extract in preparation of a blood lipid-lowering composition, and belongs to the technical field of functional food, and comprises the following components in mass parts: water-soluble tomato extract 50-100 parts, morchella esculenta extract 30-50 parts, catalpa seed extract 20-30 parts, ampelopsis grossedentata extract 5-10 parts, bitter gourd extract 5-10 parts, green tea extract 5-10 parts, rye ferment 20-30 parts and white kidney bean extract 10-20 parts. The application takes the water-soluble tomato extract as a main raw material, and is compounded with various plant extracts which are edible and medicinal, and each component plays a synergistic role in three levels of intestinal tract, cells and organs to reduce blood lipid level. The application solves the problem that in the prior art, due to single action target point of blood lipid-lowering products and side effect risk, it is difficult to realize multi-target point synergistic regulation of blood lipid and the safety is limited, and has application potential in preparation of blood lipid-lowering functional food.

Provided are the use of Collinsella shenzhenensis in treating and / or preventing inflammation-related diseases, cardiovascular diseases, and a composition for treating and / or preventing inflammation-related diseases, cardiovascular diseases, including a pharmaceutical product, a beverage, a food product, or an animal feed composition, etc., and a method for improving intestinal lesions of a mammal, reducing blood lipid levels of a mammal, controlling weight loss of a mammal, and / or reducing disease activity index (DAI) of a mammal.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a hypecoum erectum composition for treating a non-alcoholic fatty liver disease and a preparation method of the hypecoum erectum composition. The hypecoum erectum composition is prepared from the following components: hypecoum erectum ketone and juglantin, wherein the mass ratio of the hypecoum erectum ketone to the juglantin is 1: (0.3-0.5). Experimental results show that the hypecoum erectum composition can improve liver function and liver lesion degree by reducing blood fat level, liver lipid accumulation and slowing down liver inflammation.

The invention belongs to the technical field of basic medicine scientific research, and particularly relates to a method for rapidly constructing a mouse atherosclerosis model by using sorafenib. According to the method, the original molding period of 12 weeks or longer is shortened to 8 weeks, and the problem of long molding time is successfully solved; in addition, the atherosclerosis mouse model constructed by the method has a very remarkable atherosclerosis effect (the blood fat levels TC, TG and HDL-C are higher); the atherosclerotic aorta plaque area is larger, the blood vessel stenosis is more serious, and foam cells in the aortic valve are increased.

The invention discloses an edible and medicinal composition with effects of lowering lipid and protecting heart and brain as well as a preparation method and application of the edible and medicinal composition, and belongs to the technical field of functional foods. The food and medicine homologous composition is prepared from three food and medicine homologous raw materials including broccoli seeds, lucid ganoderma and radix puerariae. Broccoli seeds are heated, dried and smashed, and broccoli seed powder is obtained; the preparation method comprises the following steps: uniformly mixing crushed lucid ganoderma, radix puerariae and broccoli seed powder according to a ratio, heating and extracting, concentrating the obtained filtrate, and carrying out spray drying to obtain a core composition; and adding the auxiliary active composition into the core composition, and uniformly mixing to obtain the edible and medicinal composition with the effects of lowering lipid and protecting heart and brain. The food and medicine homologous composition can be prepared into a multi-layer tablet with a core / shell structure, and the multi-layer tablet can be eaten as a functional food or health-care food with the functions of reducing blood fat, resisting oxidation or protecting heart and cerebral vessels. Animal experiments and crowd feeding trials show that the composition has the effect of regulating the overall metabolism of the body, can reduce the blood fat level and regulate intestinal flora, and has a good auxiliary relieving effect on symptoms of cardiovascular and cerebrovascular related diseases.

The application provides a cardiovascular and cerebrovascular disease risk prediction method and system, relates to the technical field of data processing, and the method comprises the following steps: acquiring real-time physiological parameters of a target user, including dynamic blood pressure fluctuation rate, serum lipoprotein level, heart rate variability frequency domain index and sleep apnea hypopnea index; preprocessing the real-time physiological parameters, extracting the instantaneous waveform features of the blood pressure signal by using wavelet transform, and extracting the features related to the health condition, including blood pressure level, blood lipid level, blood glucose level, electrocardiogram abnormality index and cardiac ultrasound abnormality index, to form a feature vector set. Through the acquisition of the real-time physiological parameters, the preprocessing to form the feature vector set, the optimization by the phosphorus shrimp swarm algorithm, the construction of a three-level fusion model, the final accurate evaluation of the cardiovascular and cerebrovascular disease risk degree of the target user and the output of the early warning information, the accuracy and timeliness of the cardiovascular and cerebrovascular disease risk prediction are effectively improved.

The invention belongs to the technical field of traditional Chinese medicines, and discloses a traditional Chinese medicine preparation for treating metabolic syndrome, which is prepared from the following raw material medicines in parts by weight: 10-20 parts of lotus leaf, 5-15 parts of hawthorn, 5-15 parts of salvia miltiorrhiza, 10-20 parts of cassia seed, 5-15 parts of chrysanthemum, 20-40 parts of corn stigma, 5-15 parts of mulberry leaf, 10-20 parts of poria cocos, 5-15 parts of rhizoma alismatis, 5-15 parts of burdock root, 15-25 parts of fried radish seed and 20-40 parts of raw malt. According to the traditional Chinese medicine composition, heat clearing, diuresis promoting, digestion promoting and stagnation removing are adopted as methods, and the effects of heat clearing, diuresis promoting, digestion promoting and stagnation removing and blood circulation promoting and blood stasis removing are achieved through combination of all the medicine materials for the damp-heat accumulation type metabolic syndrome. Clinical research shows that the total effective rate of the traditional Chinese medicine composition is 75.93% when the traditional Chinese medicine composition is combined with conventional western medicines to treat the metabolic syndrome and is remarkably superior to that of a pure western medicine control group (53.70%); the blood pressure, the body mass index, the waist-hip ratio, the fasting blood glucose, the fasting insulin, the insulin resistance index and the blood fat level of a patient can be remarkably reduced, the high-density lipoprotein cholesterol can be increased, and obvious adverse effects are avoided. The traditional Chinese medicine composition is precise and appropriate in formula, exact in curative effect and high in safety, and has a good clinical application prospect.